Jazz Pharmaceuticals JAZZ Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's intangibles (net)?
- Jazz Pharmaceuticals (JAZZ) reported intangibles (net) of $4.2B in Q1 2026.
- How has Jazz Pharmaceuticals's intangibles (net) changed year-over-year?
- Jazz Pharmaceuticals's intangibles (net) decreased by 10.9% year-over-year, from $4.72B to $4.2B.
- What is the long-term trend for Jazz Pharmaceuticals's intangibles (net)?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's intangibles (net) has grown at a 15.1% compound annual growth rate (CAGR), from $2.2B to $4.43B.
- What does intangibles (net) mean?
- The value of non-physical assets like patents and intellectual property, minus amortization.
- How do you interpret intangibles (net)?
- An increase typically follows major acquisitions or successful product development, while a decrease reflects amortization or potential impairment.
- How does intangibles (net) compare across companies?
- Critical for biopharma; peers with high R&D output or M&A activity will show higher balances.